Phase 4Completed
Investigating Different Anticoagulants for Renal Replacement Therapy (RICH)
Regional Citrate Versus Systemic Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury
- Sponsor
- University Hospital Muenster (Academic or other)
- Enrollment
- 638 enrolled
- Conditions
- Acute Kidney Injury
- Interventions
- Heparin; Citrate
- Ages
- adults, older adults
- Registry
- NCT02669589, EUCTR2014-004854-33
Full record on ClinicalTrials.gov
From the registry
The aim of this study is to evaluate the effect of regional citrate anticoagulation within the scope of continuous renal replacement (CRRT) in critically ill patients with acute kidney injury (AKI) on filter life span and 90-day all cause mortality.
Primary outcomes
- CRRT-filter life span in hours
- Overall survival in a 90day follow-up period
History
Last registry update
Study completion
Primary completion
Started
Registered
Papers citing this trial
- Evaluation of Proenkephalin A 119-159 for liberation from renal replacement therapy: an external, multicenter pilot study in critically ill patients with acute kidney injury
Critical care (London, England)
- Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial
JAMA
- Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial
BMJ open